Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833448 | 1.00 | PTPN1 (0.48) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL15833624 | 1.00 | PTPN1 (0.48) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL8354052 | 0.95 | PTPN1 (0.49) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL18755602 | 0.95 | PTPN1 (0.49) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL8353566 | 0.94 | PTPN1 (0.50) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL9179303 | 0.93 | PTPN1 (0.52) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL14725505 | 0.90 | LMNA (0.43) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL14978161 | 0.89 | USP2 (0.50) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL21101101 | 0.89 | USP2 (0.50) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL10177584 | 0.89 | USP2 (0.50) | PTPN1USP2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | PTPN1 2123/4885USP2 2187/4885MEN1 2422/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | PTPN1 3225/4885USP2 1457/4885MEN1 2378/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | PTPN1 2140/4885USP2 2206/4885MEN1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.